Edwards Lifesciences Corporation $EW Shares Sold by Glenview Trust co

Key Points

• Glenview Trust co reduced its stake in Edwards Lifesciences by 50.5% during the 1st quarter, selling over 180,000 shares and now holding 176,908 shares valued at approximately $12.82 million.
• Edwards Lifesciences reported $1.53 billion in revenue for the last quarter, surpassing expectations, with earnings of $0.67 per share, beating analyst estimates of $0.62.
• Analysts have recently increased their price targets for Edwards Lifesciences, with Barclays raising theirs from $90.00 to $95.00 and Royal Bank Of Canada from $85.00 to $89.00, indicating a growing confidence in the company's performance.

Glenview Trust co trimmed its holdings in shares of Edwards Lifesciences Corporation (NYSE:EW - Free Report) by 50.5% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 176,908 shares of the medical research company's stock after selling 180,654 shares during the period. Glenview Trust co's holdings in Edwards Lifesciences were worth $12,822,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also bought and sold shares of the business. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its stake in Edwards Lifesciences by 4.1% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 6,783,568 shares of the medical research company's stock valued at $491,673,000 after acquiring an additional 264,311 shares during the period. Woodline Partners LP lifted its stake in Edwards Lifesciences by 7,805.0% during the 1st quarter. Woodline Partners LP now owns 825,358 shares of the medical research company's stock valued at $59,822,000 after acquiring an additional 814,917 shares during the period. MBB Public Markets I LLC acquired a new stake in Edwards Lifesciences during the 1st quarter valued at approximately $313,000. Vancity Investment Management Ltd acquired a new stake in Edwards Lifesciences during the 1st quarter valued at approximately $9,367,000. Finally, Caxton Associates LLP acquired a new stake in Edwards Lifesciences during the 1st quarter valued at approximately $370,000. 79.46% of the stock is currently owned by institutional investors and hedge funds.

Edwards Lifesciences Stock Performance

NYSE:EW opened at $79.84 on Wednesday. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.87 and a current ratio of 4.68. The company has a fifty day moving average of $78.86 and a two-hundred day moving average of $75.29. The stock has a market capitalization of $46.87 billion, a PE ratio of 11.49, a P/E/G ratio of 3.87 and a beta of 1.07. Edwards Lifesciences Corporation has a fifty-two week low of $64.00 and a fifty-two week high of $83.00.

Edwards Lifesciences (NYSE:EW - Get Free Report) last posted its quarterly earnings data on Thursday, July 24th. The medical research company reported $0.67 earnings per share for the quarter, topping analysts' consensus estimates of $0.62 by $0.05. The company had revenue of $1.53 billion during the quarter, compared to analysts' expectations of $1.49 billion. Edwards Lifesciences had a net margin of 72.96% and a return on equity of 15.01%. The firm's revenue for the quarter was up 11.9% on a year-over-year basis. During the same period in the prior year, the business posted $0.70 earnings per share. Edwards Lifesciences has set its Q3 2025 guidance at 0.540-0.60 EPS. FY 2025 guidance at 2.400-2.500 EPS. As a group, research analysts forecast that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts recently issued reports on the stock. Royal Bank Of Canada boosted their target price on shares of Edwards Lifesciences from $85.00 to $89.00 and gave the company an "outperform" rating in a research note on Friday, July 25th. Barclays boosted their target price on shares of Edwards Lifesciences from $90.00 to $95.00 and gave the company an "overweight" rating in a research note on Friday, July 25th. Wall Street Zen upgraded shares of Edwards Lifesciences from a "buy" rating to a "strong-buy" rating in a research note on Saturday, August 30th. Daiwa America upgraded shares of Edwards Lifesciences from a "hold" rating to a "strong-buy" rating in a research note on Tuesday, July 29th. Finally, The Goldman Sachs Group reiterated a "buy" rating on shares of Edwards Lifesciences in a research note on Friday, July 25th. Three equities research analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating, nine have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average target price of $86.45.

Insiders Place Their Bets

In other Edwards Lifesciences news, VP Daniel J. Lippis sold 4,114 shares of the company's stock in a transaction on Monday, July 28th. The shares were sold at an average price of $79.46, for a total transaction of $326,898.44. Following the completion of the transaction, the vice president directly owned 22,002 shares in the company, valued at approximately $1,748,278.92. This represents a 15.75% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider Larry L. Wood sold 8,950 shares of the company's stock in a transaction on Monday, June 16th. The stock was sold at an average price of $75.23, for a total transaction of $673,308.50. Following the sale, the insider directly owned 206,900 shares of the company's stock, valued at $15,565,087. The trade was a 4.15% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 22,014 shares of company stock valued at $1,698,844 over the last 90 days. 0.34% of the stock is currently owned by company insiders.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.